C5 (Complement Component 5) Drug Discovery Landscape & Assay Solutions
- By admin
- 12 Aug 2026
- Comments
Market Intelligence, Clinical Progress, and High-Purity Reagents for Complement-Mediated Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for C5 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | Human C5 Recombinant Protein (Wild-Type & R885H Mutant) — Full-length, Sequence Verified, High purity (>95%), Endotoxin <1 EU/µg. HEK293 Expressed (Native Glycosylation). | View C5 Products |
| Ortholog | Cynomolgus C5 / Mouse C5 Protein — For cross-species PK/PD and toxicity studies. Species-specific sequences verified. | View C5 Products |
| Gene Delivery | C5 ORF Lentivirus / Promise-ORF — Full-length ORF for stable overexpression in CHO/HEK293 cells. | View C5 Products |
| Benchmark Ab | Anti-C5 (Eculizumab / Ravulizumab / Crovalimab Biosimilar Sequences) — Recombinant positive control for inhibition assays. Sequence Verified. | View C5 Products |
| Validator | C5 siRNA Set — For knockdown validation in cell-based hemolysis rescue and hepatocyte specificity checks. | View C5 Products |
| Related Target: C3 | Complement C3 — Upstream complement component for combination therapy screening. | View C3 Products |
| Related Target: C5aR1 | C5a Receptor 1 (CD88) — Target for C5a-specific pathway inhibition (inflammation vs cytolysis). | View C5aR1 Products |
Critical Assay Challenges & TarMart Advantages
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species Cyno/Mouse evaluation for preclinical safety | Human / Cynomolgus / Mouse C5 ortholog proteins available with >95% purity, sequence verified by mass spec, matched glycosylation profiles (HEK293). |
| Hemolysis assay reconstitution (Functional purity) | Low-endotoxin (<1 EU/µg), high-specific-activity C5 protein for classical pathway reconstitution. |
| C5a vs C5b inhibition specificity screening | Domain-specific antigens and cleavage-resistant mutants available upon request. |
| Eculizumab Resistance Screening (R885H Polymorphism) | Human C5 WT and R885H Mutant proteins, Sequence Verified, >95% purity, SPR/BLI compatible. |
| C5 Convertase Cleavage Blockade Confirmation | Endotoxin-controlled (<1 EU/µg), native conformation C5 for functional cleavage assays. |
| Off-target specificity & knockdown controls | C5 siRNA included; C3/C4 homolog panel available for strict counter-screening. |
| Lack of reliable clinical controls | Clinical Benchmark Antibodies (Eculizumab/Ravulizumab/Crovalimab biosimilar sequences) included with endotoxin-controlled specs. |
| Complex multi-chain processing verification | Native HEK293 Expression ensures correct post-translational modifications and physiological folding. |
Live C5 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The C5 inhibitor market is transitioning from intravenous monoclonal antibody infusions (Eculizumab era) toward patient-friendly modalities: subcutaneous long-acting antibodies (Ravulizumab), oral small molecules (Avacincaptad, BCX9930), and RNA interference therapeutics (Cemdisiran). While Paroxysmal Nocturnal Hemoglobinuria (PNH) and Atypical Hemolytic Uremic Syndrome (aHUS) remain the anchor indications, the next wave of R&D targets Geographic Atrophy (GA) secondary to AMD, IgA Nephropathy, and Myasthenia Gravis (gMG). Key shifts include: (1) intravenous-to-subcutaneous transition for improved patient compliance; (2) development of recycling antibodies (e.g., Crovalimab) to extend dosing intervals; (3) mandatory validation against C5 resistance polymorphisms (e.g., R885H) for ethnic-specific coverage. The demand for high-fidelity C5 antigens, mutant proteins, and species-crossover reagents has intensified for preclinical PK/PD modeling and resistance screening.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Long-Acting mAb | AstraZeneca/Alexion, Regeneron | PNH, aHUS, gMG | High-purity C5 antigen for SPR & convertase-blocking validation; Cyno cross-reactivity panel. |
| Oral Small Molecule | Iveric Bio, BioCryst | GA (AMD), PNH | C5 mutant proteins (resistance screening), Cyno/Mouse cross-reactivity. |
| RNAi (siRNA) | Alnylam, Arrowhead, Novartis | PNH (investigational), complement diseases | Stable cell line construction (Lentivirus ORF for rescue experiments); liver C5 secretion quantification. |
| Pegylated Aptamer | Avacincaptad pegol (Iveric) | Geographic Atrophy | C5a/C5b cleavage product detection assays. |
| Recycling Antibody | Roche/Chugai | PNH | pH-Dependent Affinity Assays (Need Native Glycosylation). |
| Macrocyclic Peptide / Small Protein | UCB (Zilucoplan), Amyndas | gMG, PNH | C5-ligand competition assays; pH-dependent binding stability; SC concentration screens. |
Molecular Differentiation & Assay Strategy
To develop best-in-class C5 therapeutics, differentiation must address: (1) Delivery – Subcutaneous or oral routes require high-concentration formulations with low endotoxin (<1 EU/µg); TarMart's HEK293-expressed proteins meet this rigor. (2) Resistance Coverage – The R885H mutation abolishes Eculizumab binding; parallel screening against WT and R885H C5 is now standard. TarMart provides both variants with >95% purity. (3) Mechanism – True blockade of C5 convertase cleavage, not mere binding, is essential. Functional hemolysis assays (CH50) demand native-conformation C5. (4) Safety – Counter-screening against C3/C4 to avoid off-target cross-reactivity. TarMart's siRNA and homolog panels enable strict specificity checks.